ECSP055530A - Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva - Google Patents
Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectivaInfo
- Publication number
- ECSP055530A ECSP055530A EC2005005530A ECSP055530A ECSP055530A EC SP055530 A ECSP055530 A EC SP055530A EC 2005005530 A EC2005005530 A EC 2005005530A EC SP055530 A ECSP055530 A EC SP055530A EC SP055530 A ECSP055530 A EC SP055530A
- Authority
- EC
- Ecuador
- Prior art keywords
- preparations
- relates
- substituted
- stratriens
- strateges
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se relaciona con nuevos estratrienos 9 -sustituidos de la fórmula general I, donde R3, R7, R7', R13, R16 y R17 y R17' tienen los significados indicados en la descripción, así como R9 es un radical alquenilo de cadena lineal o ramificada, opcionalmente halogenado de modo parcial o total con 2 a 6 átomos de carbono, un radical etinilo o prop-1-inilo, como ingredientes activos farmacéuticos, que presentan in vitro una mayor afinidad en preparaciones de receptores de estró-geno de próstata de rata que en preparaciones de receptores de estrógeno de útero de rata y que presentan in vivo, con preferencia, un efecto preferencial en el ovario en comparación con el útero. El invento también se refiere a la prepara-ción de estos estratrienos, a su aplicación terapéutica y a formas de administra-ción farmacéuticas que contienen los nuevos compuestos. La invención se refie-re, además, al uso de estos compuestos para el tratamiento de enfermedades y estados originados por deficiencia de estrógenos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10226326A DE10226326A1 (de) | 2002-06-11 | 2002-06-11 | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP055530A true ECSP055530A (es) | 2005-03-10 |
Family
ID=29723144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005005530A ECSP055530A (es) | 2002-06-11 | 2005-01-10 | Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1517914B1 (es) |
| JP (1) | JP4615998B2 (es) |
| KR (1) | KR101006612B1 (es) |
| CN (1) | CN1293090C (es) |
| AR (1) | AR040188A1 (es) |
| AT (1) | ATE303397T1 (es) |
| AU (1) | AU2003242683B9 (es) |
| BR (1) | BR0312140A (es) |
| CA (1) | CA2486495C (es) |
| CR (1) | CR10289A (es) |
| CU (1) | CU23414B7 (es) |
| DE (2) | DE10226326A1 (es) |
| DK (1) | DK1517914T3 (es) |
| EA (1) | EA008442B1 (es) |
| EC (1) | ECSP055530A (es) |
| ES (1) | ES2248770T3 (es) |
| HR (1) | HRP20050009B1 (es) |
| IL (1) | IL165321A (es) |
| MX (1) | MXPA04012491A (es) |
| NO (1) | NO329563B1 (es) |
| PE (1) | PE20040613A1 (es) |
| PL (1) | PL209910B1 (es) |
| RS (1) | RS50878B (es) |
| TW (1) | TWI286140B (es) |
| UA (1) | UA78062C2 (es) |
| UY (1) | UY27844A1 (es) |
| WO (1) | WO2003104253A2 (es) |
| ZA (1) | ZA200500217B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10027887A1 (de) | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| WO2005051401A2 (en) * | 2003-11-26 | 2005-06-09 | Schering Aktiengesellschaft | Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol |
| US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
| DE102005057224A1 (de) * | 2005-11-29 | 2007-05-31 | Bayer Schering Pharma Ag | Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| CA2714598A1 (en) * | 2008-02-13 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system with stabilising effect |
| EP2143432A1 (en) | 2008-07-11 | 2010-01-13 | Bayer Schering Pharma AG | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer |
| EP2358351A1 (en) * | 2008-11-21 | 2011-08-24 | Bayer Pharma Aktiengesellschaft | Drug delivery system |
| EP3185881B1 (en) | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| CN113056473A (zh) * | 2018-09-07 | 2021-06-29 | 达特茅斯学院托管理事会 | C19支架和甾体及其使用和制造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2336432A1 (de) * | 1973-07-13 | 1975-01-30 | Schering Ag | 3.17.18-trihydroxy-1.3.5(10)-oestratriene |
| US6154158A (en) * | 1998-06-30 | 2000-11-28 | Qualcomm Incorporated | Digital-to-analog converter D.C. offset correction comparing converter input and output signals |
| DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
| PT1226155E (pt) * | 1999-11-02 | 2007-07-26 | Bayer Schering Pharma Ag | 18-nor-esteróides como estrogénios selectivamente activos |
| IL152248A0 (en) * | 2000-04-12 | 2003-05-29 | Schering Ag | 8beta-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS |
-
2002
- 2002-06-11 DE DE10226326A patent/DE10226326A1/de not_active Ceased
-
2003
- 2003-06-10 PE PE2003000575A patent/PE20040613A1/es not_active Application Discontinuation
- 2003-06-11 BR BR0312140-2A patent/BR0312140A/pt not_active IP Right Cessation
- 2003-06-11 ES ES03757065T patent/ES2248770T3/es not_active Expired - Lifetime
- 2003-06-11 UY UY27844A patent/UY27844A1/es not_active Application Discontinuation
- 2003-06-11 TW TW092115863A patent/TWI286140B/zh not_active IP Right Cessation
- 2003-06-11 MX MXPA04012491A patent/MXPA04012491A/es active IP Right Grant
- 2003-06-11 PL PL373090A patent/PL209910B1/pl not_active IP Right Cessation
- 2003-06-11 EA EA200401544A patent/EA008442B1/ru not_active IP Right Cessation
- 2003-06-11 DK DK03757065T patent/DK1517914T3/da active
- 2003-06-11 CA CA2486495A patent/CA2486495C/en not_active Expired - Fee Related
- 2003-06-11 DE DE50301116T patent/DE50301116D1/de not_active Expired - Lifetime
- 2003-06-11 JP JP2004511321A patent/JP4615998B2/ja not_active Expired - Fee Related
- 2003-06-11 EP EP03757065A patent/EP1517914B1/de not_active Expired - Lifetime
- 2003-06-11 RS YUP-1070/04A patent/RS50878B/sr unknown
- 2003-06-11 CN CNB038135027A patent/CN1293090C/zh not_active Expired - Fee Related
- 2003-06-11 AU AU2003242683A patent/AU2003242683B9/en not_active Ceased
- 2003-06-11 HR HRP20050009AA patent/HRP20050009B1/hr not_active IP Right Cessation
- 2003-06-11 AT AT03757065T patent/ATE303397T1/de active
- 2003-06-11 AR ARP030102079A patent/AR040188A1/es active IP Right Grant
- 2003-06-11 WO PCT/EP2003/006172 patent/WO2003104253A2/de not_active Ceased
- 2003-06-11 KR KR1020047020133A patent/KR101006612B1/ko not_active Expired - Fee Related
- 2003-11-06 UA UAA200500212A patent/UA78062C2/uk unknown
-
2004
- 2004-11-22 IL IL165321A patent/IL165321A/en not_active IP Right Cessation
- 2004-12-10 CU CU20040282A patent/CU23414B7/es not_active IP Right Cessation
-
2005
- 2005-01-10 NO NO20050127A patent/NO329563B1/no not_active IP Right Cessation
- 2005-01-10 EC EC2005005530A patent/ECSP055530A/es unknown
-
2006
- 2006-01-10 ZA ZA200500217A patent/ZA200500217B/en unknown
-
2008
- 2008-09-16 CR CR10289A patent/CR10289A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1272505T3 (da) | 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater | |
| GT199800021A (es) | Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos. | |
| CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
| SV2002000357A (es) | Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo ref pc10748amag/bb | |
| CR10289A (es) | "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional) | |
| EA201201221A1 (ru) | Фармацевтическая композиция для контрацепции и заместительной гормональной терапии | |
| PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
| PE20080995A1 (es) | 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
| PA8613001A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| UY26665A1 (es) | Estratrienos sustituidos como estrógenos selectivamente activos | |
| DOP2010000017A (es) | Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva | |
| PE20020466A1 (es) | Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama | |
| PE20050207A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas | |
| UY26967A1 (es) | Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.- | |
| AR036227A1 (es) | USO DE LIGANDOS SELECTIVOS PARA ERa PARA REGULAR LA FERTILIDAD. | |
| TH114620A (th) | 8-บีตา-ซับสทิทิวเทด เอสทราไทรอีนที่เป็นเอสโทรเจนที่ออกฤทธิ์อย่างมีอำนาจเลือก | |
| AR033260A1 (es) | Nueva composicion hormonal y su utilizacion | |
| AR035590A1 (es) | Derivados 8 beta-sustituidos de 11beta-pentil- y 11beta-hexil-estra-1,3,5 (10)-trieno, las composiciones farmaceuticas que los contienen y el uso de estos derivados para preparar medicamentos | |
| ES2177421B1 (es) | Composicion para el tratamiento de trastornos por ingesta de alcohol y similares y su procedimiento de preparacion. | |
| AR030018A1 (es) | Derivados de benzo(d)(1,3)oxazin-2-ona, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar medicamentos como moduladores receptores de progesterona | |
| HN1999000180A (es) | Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migra¥a. | |
| AR044184A1 (es) | Metodo para el manejo terapeutico de la proliferacion extrauterina de tejido endometrial, dolor pelvico cronico y obstruccion de las trompas de falopio, las composiciones farmaceuticas utiles para la aplicacion de dicho metodo y el uso de un antagonista de lhrh para la preparacion de dichos medicame |